Aeon Raises Seed Round Led by Araya Ventures

Aeon, a Zurich-based preventive healthcare company, has raised a Seed round led by Araya Ventures. The round also includes Calm/Storm Ventures, Concentric, Kadmos Capital, GoHub Ventures, N&V Capital, and Bigwave Capital. The funding date is September 14, 2026.

What Aeon Does

Aeon offers AI-powered health check-ups that combine whole-body MRI with blood diagnostics covering more than 100 biomarkers and genetic risk analysis. The company was founded in 2023.

The core of the offering is a continuous, longitudinal health record. Rather than treating a check-up as a one-time snapshot, Aeon's platform accumulates data over time so that AI models can detect trends, flag deviations early, and predict individual health risks before disease develops.

Expanding Beyond Imaging

In September 2026, Aeon acquired Aware Health, a Berlin-based blood diagnostics provider. That acquisition allows Aeon to pair whole-body imaging with recurring consumer blood testing across Switzerland and Germany.

The combination is significant for the company's model. Whole-body MRI provides periodic, high-resolution imaging, while recurring blood testing provides a much higher-frequency data stream. Together they feed the longitudinal record that Aeon's AI models rely on to identify changes over time.

Investor Syndicate

The Seed round brings together a broad group of backers:

Lead: Araya Ventures
Participants: Calm/Storm Ventures, Concentric, Kadmos Capital, GoHub Ventures, N&V Capital, Bigwave Capital

The breadth of the syndicate suggests interest across both healthcare and technology-focused investors, consistent with a company operating at the intersection of diagnostics, imaging, and AI-driven risk prediction.

Why This Round Matters

Preventive healthcare models depend on data density. The more frequently a patient is measured, and the more dimensions captured, the more useful trend detection becomes. Aeon's strategy — combining imaging, broad blood biomarker panels, and genetic risk analysis into a single longitudinal record — is aimed squarely at that requirement.

The acquisition of Aware Health adds recurring blood testing capability and a presence in the German market alongside Switzerland. That gives Aeon both a wider geographic footprint and a higher-frequency data source to support its predictive models.

What to Watch

How Aeon integrates Aware Health's blood diagnostics operations with its existing imaging-based check-ups across Switzerland and Germany.
Whether the longitudinal record translates into demonstrable early-detection outcomes as the dataset matures.
Adoption of recurring consumer blood testing as a complement to periodic whole-body MRI.

Summary

Company: Aeon
Headquarters: Zurich
Founded: 2023
Product: AI-powered health check-ups combining whole-body MRI, blood diagnostics across 100+ biomarkers, and genetic risk analysis
Stage: Seed
Lead investor: Araya Ventures
Other investors: Calm/Storm Ventures, Concentric, Kadmos Capital, GoHub Ventures, N&V Capital, Bigwave Capital
Funding date: September 14, 2026
Recent acquisition: Aware Health (Berlin-based blood diagnostics provider), September 2026